Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.3
-72x
40%
—
469.89%
40%
—
5 Years
Score3.3
Net Growth-72x
Net Trend40%
Net Income Consistency—
Rev Growth469.89%
Rev Trend40%
Revenue Consistency—
Abcellera Biologics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 233M to $ 75M and net income went from $ 118M to -$ 146M. Revenue increased in 2 of those 5 years; net income in 2.
Abcellera Biologics Inc currently holds a 5-year HDB Score of 3.3 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 10.36 | — |
1 Year2025-08-12 | $ 4.27 | 142.51% |
5 Years2021-08-12 | $ 15.19 | -31.83% |
All Time2020-12-11 | $ 58.90 | -82.42% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2020-12-11 |
|---|---|---|---|---|
| Price | $ 10.36 | $ 4.27 | $ 15.19 | $ 58.90 |
| Return | — | 142.51% | -31.83% | -82.42% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 66M | -$ 164M | $ 540M |
| 2025 | $ 75M | -$ 146M | $ 533M |
| 2024 | $ 28M | -$ 162M | $ 625M |
| 2023 | $ 38M | -$ 146M | $ 760M |
| 2022 | $ 485M | $ 158M | $ 886M |
| 2021 | $ 11M | -$ 2M | $ 722M |
| IPO2020 | $ 233M | $ 118M | $ 594M |
Explore beyond ABCL
You're looking at Abcellera Biologics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
